Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
S&P Biotech SPDR
(NY:
XBI
)
99.27
+2.24 (+2.31%)
Official Closing Price
Updated: 8:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about S&P Biotech SPDR
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules
April 13, 2023
A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug.
Via
Benzinga
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications
April 12, 2023
New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this...
Via
Benzinga
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead
April 11, 2023
In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating...
Via
Benzinga
Time to Spring-Clean...Your Stock Portfolio
April 10, 2023
Plus, Howard Marks, co-founder of Oaktree Capital Management, joins the podcast to discuss topics including China's effect on inflation in the U.S.
Via
The Motley Fool
April Is Busting Out For Healthcare And Biotech
April 10, 2023
Last week was a good week for healthcare stocks and most large cap biopharmaceutical stocks resumed an upward trend.
Via
Talk Markets
FDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits
April 06, 2023
Via
Benzinga
Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags
April 03, 2023
It was very difficult to make money in Q1 trading healthcare or biotech ETFs because of the sharp rally in other sectors. Nonetheless, there were two big winners.
Via
Talk Markets
The Stock Market Rally May Fizzle The Week Of April 3
April 02, 2023
I think what we’ve seen over the last week or two has been driven by systematic trading and rebalancing of portfolios, as investors have sold financials and moved into mega-cap technology names. But...
Via
Talk Markets
Biotech And Life Science Trades: Q1 2023 Performance By The Numbers
April 01, 2023
Despite a strong month and a great finish to the quarter, many traders remain cautious about the market. It’s been a volatile time after the collapse of Silicon Valley Bank, but the first quarter of...
Via
Talk Markets
“Don’t Stop Believin'” Stock Market (And Sentiment Results)
March 30, 2023
In this week’s AAII Sentiment Survey result, bullish percent ticked up to 22.5% from 20.9% the previous week.
Via
Talk Markets
This Blue Chip Dividend Stock Should Return to Form When the Risk Premium Flips
March 30, 2023
T-bills may be the flavor of the month, but history has shown this top biotech stock is a far better long-term investment.
Via
The Motley Fool
The 3 Best Growth Stocks to Buy in the Biotech Sector
March 29, 2023
These three biotech growth stocks are brimming with potential and could offer massive upside for patient investors.
Via
InvestorPlace
Can Healthcare Stocks Survive Macro Headwinds?
March 27, 2023
Healthcare stocks are supposed to be defensive plays in a choppy market. However, over the past 18 months, the XLV is flat and down 6% over one year.
Via
Talk Markets
Want Diversified Upside in Biotechnology? Check out LABU
March 22, 2023
Watch the Direxion Daily S&P 500 Biotech Bull 3X Shares (NYSEARCA: LABU) if you want a speculative play in the biotechnology industry with amplified volatility.
Via
MarketBeat
Topics
ETFs
Stocks
Exposures
US Equities
US Judge Weighs Nationwide Ban On Abortion Pills
March 16, 2023
U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory approval of the abortion pill mifepristone was proper. The judge is...
Via
Benzinga
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
March 15, 2023
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.
Via
InvestorPlace
Biotech Stocks And The SVB Collapse — Here's What We Know
March 14, 2023
The collapse of SVB will have a big impact on early-stage, venture-backed companies.
Via
Investor's Business Daily
Silicon Valley Bank Meltdown Hits Healthcare Sector As Well
March 13, 2023
The Federal Deposit Insurance Corporation (FDIC) closed Silicon Valley Bank, the banking arm of SVB Financial Group (NASDAQ:
Via
Benzinga
Small Cap Biotechs Slammed By SVB Collapse
March 13, 2023
Nothing like a banking crisis to start off a weekend. But maybe by the end of this upcoming week of turmoil we'll worry less about inflation.
Via
Talk Markets
6 Stock Market Thoughts For The Week Of March 13
March 12, 2023
A flight to safety seemed to be at play this week, with the market seeking safety first and asking questions later. This is not unusual, and once the situation is resolved, much of the decline in rates...
Via
Talk Markets
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
March 10, 2023
New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per...
Via
Benzinga
FDA Seeks 10% Increase In Biden's FY 2024 Budget, Proposes Enhancing Regulatory Authorities
March 10, 2023
Via
Benzinga
Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading
March 06, 2023
Over the past week, the market had a nice uptick making it harder for defensive sectors like healthcare to get traction up only 0.51% and down almost 5% YTD.
Via
Talk Markets
FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug'
March 01, 2023
Via
Benzinga
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
February 05, 2023
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy?
Via
Talk Markets
Stryker, DaVita And These 2 ETFs: CNBC's 'Final Trades'
January 31, 2023
On CNBC’s "Halftime Report Final Trades," Liz Young of BNY Mellon Investment Management named the SPDR S&P Biotech ETF (NYSE: XBI), saying if you "want growth,
Via
Benzinga
Sector Shift Stalls Healthcare Stocks But Biotech Shows Gains In January
January 30, 2023
Biotech stocks are off to a great start in 2023 with the IBB up 4.5% and the XBI up 7.7%.
Via
Talk Markets
2 ETFs That Can Set You Up for Life
January 25, 2023
Simplifying your investment strategy can help minimize your risk while still allowing you to earn some great returns.
Via
The Motley Fool
Healthcare Sector Is Lagging As We Enter 2022 Earnings Season
January 23, 2023
The healthcare sector is perceived as defensive but in 2023 there is more investor appetite for risk based on the QQQ comeback and the XBI strength.
Via
Talk Markets
The Fed Should Stop Right Now
January 19, 2023
A pause to refresh or a mild pullback would be good for the stock market after running hot and heavy. On Wednesday, we saw weaker economic data in retail sales. Unlike previous soft data, the stock...
Via
Talk Markets
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.